Current Research Trials 

Updated August 2025

Arrhythmias

ANTHOS-LILAC-TIMI 76 (Active/Enrolling): A study to evaluate the efficacy and safety of Abelacimab in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation.(https://clinicaltrials.gov/study/NCT05712200)

CONFORM (Active/Enrolling): Evaluating the safety and effectiveness of the CLAAS device with currently available left atrial appendage occlusion (LAAO) systems for patients with non-valvular atrial fibrillation.(https://clinicaltrials.gov/study/NCT05147792)

REAL-AF (Active/Enrolling): This registry aims to gather real-world clinical data on the use of radiofrequency (RF) technologies for treating paroxysmal (PAF) and persistent (PsAF) atrial fibrillation through catheter ablation. The data will help evaluate the safety, efficiency, and long-term effectiveness of these new RF technologies in patients with PAF and PsAF.
(https://clinicaltrials.gov/study/NCT04088071)

Lipoprotein (a)

    • New trials beginning in Fall 2025.

Coronary Artery Disease/Acute Coronary Syndrome

DAL-GeneE-302 (Active/Enrolling): Study to evaluate the effects of Dalcetrapib on cardiovascular (CV) risk in a genetically defined population with recent acute coronary syndrome / heart attack.(https://clinicaltrials.gov/study/NCT05918861)

ORION-4 (Follow-up): A trial assessing the effects of Inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.
(https://clinicaltrials.gov/study/NCT03705234)"

TRIUMPH-J1I-MC-GZBO (Follow-up): A study to investigate the effect of retatrutide on major adverse cardiovascular and kidney problems in participants with atherosclerotic cardiovascular disease and/or chronic kidney disease, and a body mass index of ≥27 kg/m2.
(https://clinicaltrials.gov/study/NCT06383390)

PARAMOUNT (Active/Enrolling):  A prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptomatic patients with suspicion of CAD.
(https://clinicaltrials.gov/study/NCT06713239)

Victorion-1-Prevent (Follow-up): This study aims to determine if Inclisiran can reduce cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization in high-CV-risk patients without a prior major atherosclerotic cardiovascular disease (ASCVD).
(https://clinicaltrials.gov/study/NCT05739383)


Heart Failure

AURORA (Active/Enrolling): This study aims to evaluate the safety, tolerability, and efficacy of the drug BMS-986435/MYK-224 in individuals experiencing symptomatic heart failure with preserved ejection fraction (HFpEF).
(https://clinicaltrials.gov/study/NCT06122779)

COMET (Active/Enrolling): This study investigates whether Omecamtiv Mecarbil can improve outcomes for individuals with severe heart failure / HFrEF. 
(https://clinicaltrials.gov/study/NCT06736574)

HERMES (Active/Enrolling): A research study comparing Ziltivekimab to placebo in individuals with heart failure and inflammation.
(https://www.clinicaltrials.gov/study/NCT05636176)

LUX Dx Trends (Follow-up): The primary objective of this study is to collect physiological measurement data and heart failure  event data from LUX sensors that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems.
(https://clinicaltrials.gov/study/NCT04790344)

MARITIME-HF (Active/Enrolling): A study to evaluate the effectiveness and safety of Maridebart Cafraglutide (MariTide) in individuals with HF-related symptoms and risk of hospitalization in people with heart failure and obesity.
(https://www.clinicaltrials.gov/study/NCT07037459)

REBALANCE registry (Follow-up): This registry aims to gather robust scientific data on the safety and effectiveness of Barostim therapy in a commercial setting. It focuses on patients with heart failure with reduced ejection fraction (HFrEF) who have recently received the Barostim System.
(https://clinicaltrials.gov/study/NCT04502316)


Hypertension

    • None at this time.